齐卢可普兰治疗全身型肌无力(RAISE)的安全性和有效性:一项随机、双盲、安慰剂对照的3期研究
RAISE是一项在75个中心开展的随机、双盲、安慰剂对照3期试验,纳入174例乙酰胆碱受体抗体阳性全身型肌无力患者,随机接受齐卢可普兰0.3 mg/kg每日一次皮下注射或安慰剂治疗12周。齐卢可普兰组MG-ADL评分较基线的改善优于安慰剂组,不良事件发生率与安慰剂组相似。
要点
- 齐卢可普兰组MG-ADL评分最小二乘均值变化为-4.39,安慰剂组为-2.30,组间差异-2.09(p=0.0004)。
- 治疗中出现的不良事件发生率:齐卢可普兰组77%,安慰剂组70%;最常见为注射部位瘀斑。
- 齐卢可普兰组和安慰剂组严重不良事件和严重感染发生率相似,每组各1例死亡,均与研究药物无关。
核心结论
- 齐卢可普兰治疗在肌无力特异性疗效结局上显示出快速且具有临床意义的改善,安全性良好且耐受性良好,无重大安全性发现。
- 齐卢可普兰是乙酰胆碱受体抗体阳性全身型肌无力广泛患者人群的一种新的潜在治疗选择。
- 齐卢可普兰的长期安全性和有效性正在一项正在进行的开放标签扩展研究中评估。
研究设计与样本
- RAISE是一项在欧洲、日本和北美75个中心开展的随机、双盲、安慰剂对照3期试验。
- 纳入18-74岁乙酰胆碱受体抗体阳性全身型肌无力(美国肌无力基金会疾病分级II-IV级)、MG-ADL评分至少6分且定量肌无力评分至少12分的患者。
- 239例患者经筛选,174例(73%)符合条件,86例(49%)随机分配至齐卢可普兰0.3 mg/kg组,88例(51%)分配至安慰剂组。
- 参与者按1:1随机分配接受皮下齐卢可普兰0.3 mg/kg每日一次自我注射或匹配安慰剂,治疗12周。
- 主要疗效终点为改良意向治疗人群中MG-ADL评分从基线至第12周的变化。
主要发现
- 齐卢可普兰组MG-ADL评分从基线至第12周的最小二乘均值变化为-4.39(95% CI -5.28至-3.50),安慰剂组为-2.30(-3.17至-1.43),最小二乘均值差异为-2.09(-3.24至-0.95),p=0.0004。
- 治疗中出现的不良事件发生在齐卢可普兰组66例(77%)和安慰剂组62例(70%)患者中。
- 最常见的治疗中出现的不良事件为注射部位瘀斑,齐卢可普兰组14例(16%),安慰剂组8例(9%)。
- 严重治疗中出现的不良事件和严重感染的发生率在两组相似。
- 每组各1例患者死亡,齐卢可普兰组为COVID-19,安慰剂组为脑出血,均被认为与研究药物无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare disease, often accompanied by high treatment burden and with an unmet need for more efficacious and well tolerated treatments. Zilucoplan is a subcutaneous, self-administered macrocyclic peptide complement C5 inhibitor. We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis. METHODS: RAISE was a randomised, double-blind, placebo-controlled, phase 3 trial that was done at 75 sites in Europe, Japan, and North America. We enrolled patients (aged 18-74 years) with AChR-positive generalised myasthenia gravis (Myasthenia Gravis Foundation of America disease class II-IV), a myasthenia gravis activities of daily living (MG-ADL) score of least 6, and a quantitative myasthenia gravis score of at least 12. Participants were randomly assigned (1:1) to receive subcutaneous zilucoplan 0·3 mg/kg once daily by self-injection, or matched placebo, for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in MG-ADL score in the modified intention-to-treat population (all randomly assigned patients who received at least one dose of study drug and had at least one post-dosing MG-ADL score). Safety was mainly assessed by the incidence of treatment-emergent adverse events (TEAEs) in all patients who had received at least one dose of zilucoplan or placebo. This trial is registered at ClinicalTrials.gov, NCT04115293. An open-label extension study is ongoing (NCT04225871). FINDINGS: Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo. Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004). TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group). Incidences of serious TEAEs and serious infections were similar in both groups. One patient died in each group; neither death (COVID-19 [zilucoplan] and cerebral haemorrhage [placebo]) was considered related to the study drug. INTERPRETATION: Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study. FUNDING: UCB Pharma.
引用
- Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023. PMID: 37059508. doi:10.1016/S1474-4422(23)00080-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。